Monday June 26th 2017

Posts Tagged ‘info’

Study Provides Strong Evidence for Benefits of Cognitive Rehabilitation to Improve Learning and Memory in People with MS

Study Provides Strong Evidence for Benefits of Cognitive Rehabilitation to Improve Learning and Memory in People with MS

Researchers at the Kessler Foundation in New Jersey report results of a clinical trial showing that a specific type of memory training improves learning in people with MS for at least 6 months after the training has ended, and also benefits other aspects of quality of life. [Read More]

National MS Society Partners with Accelerated Cure Project’s MS Discovery Forum to Drive Research Connections for Progressive MS

National MS Society Partners with Accelerated Cure Project’s MS Discovery Forum to Drive Research Connections for Progressive MS

The National Multiple Sclerosis Society is partnering with the Accelerated Cure Project’s (ACP) Multiple Sclerosis Discovery Forum (MSDF) – an interactive online community and information portal for researchers and clinicians – to develop resources and content [Read More]

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]